Top 10 things to know about lupus activity measures

Current Rheumatology Reports

Volumn 15, Issue 6, 2013, Pages

  Thanou, Aikaterini ^a   Merrill, Joan T ^a  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

BICLA; BILAG; British Isles lupus assessment group index; Flare; Lupus activity measures; Lupus nephritis; Outcome measures; Selena flare index; SFI; SLE; SLE responder index; SLEDAI; SLEDAI 2000; SRI; SRI 50; Systemic lupus erythematosus

Indexed keywords

ARTICLE; BILAG 2004; BILAG 2004 FLARE INDEX; BILAG BASED COMPOSITE LUPUS ASSESSMENT; BRITISH ISLES LUPUS ASSESSMENT GROUP INDEX; DIAGNOSTIC PROCEDURE; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; DISEASE EXACERBATION; DISEASE SEVERITY; HUMAN; LUPUS NEPHRITIS OUTCOME MEASURES; OTGAN SPECIFIC LUPUS ACTIVITY MEASURES; OUTCOME ASSESSMENT; RELIABILITY; SELENA FLARE INDEX; SENSITIVITY AND SPECIFICITY; SLE RESPONDER INDEX; SLEDAI; SLEDAI 2000; SLEDAI 2000 RESPONSER INDEX 50; SYSTEMIC LUPUS ERYTHEMATOSUS; VALIDITY; BIOASSAY; DISABILITY; DISEASE COURSE; HEALTH STATUS; METHODOLOGY; PATHOPHYSIOLOGY; PROGNOSIS; REPRODUCIBILITY; REVIEW; SEVERITY OF ILLNESS INDEX;

DISABILITY EVALUATION; DISEASE PROGRESSION; ENDPOINT DETERMINATION; HEALTH STATUS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX;

EID: 84876164089     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-013-0334-2     Document Type: Article

References (45)

1. Griffiths B, Mosca M, Gordon C. Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Pract Res Clin Rheumatol. 2005;19:685-708. (Pubitemid 41258578)
2. Romero-Diaz J, Isenberg D, Ramsey-Goldman R. Measures of adult systemic lupus erythematosus: updated version of British Isles Lupus Assessment Group (BILAG 2004), European Consensus Lupus Activity Measurements (ECLAM), Systemic Lupus Activity Measure, Revised (SLAM-R), Systemic Lupus Activity Questionnaire for Population Studies (SLAQ), Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2 K), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). Arthritis care & research. 2011;63 Suppl 11:S37-46.
3. Albrecht J, Taylor L, Berlin JA, et al. The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol. 2005;125:889-94.
4. Furie RA, Petri MA, Wallace DJ, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 2009;61:1143-51.
5. • Wallace D, Strand V, Furie R, et al. Evaluation of Treatment Success in Systemic Lupus Erythematosus Clinical Trials: Development of the British Isles Lupus Assessment Group-Based Composite Lupus Assessment Endpoint. Arthritis Rheum. 2011;63:S894. The first description of the BILAG-Based Composite Lupus Assessment.
6. The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: measures of overall disease activity. Arthritis Rheum. 2004;50:3418-3426.
7. Gordon C, Bertsias G, Ioannidis JP, et al. EULAR points to consider for conducting clinical trials in systemic lupus erythematosus. Ann Rheum Dis. 2009;68:470-6.
8. Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992;35:630-40.
9. Buyon JP, Petri MA, Kim MY, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med. 2005;142:953-62.
10. Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med. 2005;353:2550-8. (Pubitemid 41785892)
11. Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29:288-91. (Pubitemid 34118775)
12. Touma Z, Urowitz MB, Ibanez D, Gladman DD. SLEDAI-2 K 10 days versus SLEDAI-2 K 30 days in a longitudinal evaluation. Lupus. 2011;20:67-70.
13. Gladman DD, Urowitz MB, Kagal A, Hallett D. Accurately describing changes in disease activity in Systemic Lupus Erythematosus. J Rheumatol. 2000;27:377-9. (Pubitemid 30095467)
14. • Yee CS, Farewell VT, Isenberg DA, et al. The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. Rheumatology (Oxford). 2011;50:982-8. Analysis of data from 2 large multi-center studies to determine SLEDAI-2 K sensitivity to change in disease activity over time using change in therapy as the reference standard.
15. Ward MM, Marx AS, Barry NN. Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus. J Rheumatol. 2000;27:664-70. (Pubitemid 30151343)
16. • Touma Z, Gladman DD, Ibanez D, Urowitz MB. Development and initial validation of the systemic lupus erythematosus disease activity index 2000 responder index 50. J Rheumatol. 2011;38:275-84. First detailed description of the SRI-50 definitions and scoring.
17. Touma Z, Urowitz MB, Fortin PR, et al. Systemic lupus erythematosus disease activity index 2000 responder index-50: a reliable index for measuring improvement in disease activity. J Rheumatol. 2011;38:868-73.
18. Touma Z, Gladman DD, Ibanez D, et al. Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50 enhances the ability of SLE Responder Index to identify responders in clinical trials. J Rheumatol. 2011;38:2395-9.
19. Touma Z, Urowitz MB, Taghavi-Zadeh S, et al. Systemic lupus erythematosus disease activity Index 2000 Responder Index 50: sensitivity to response at 6 and 12 months. Rheumatology (Oxford). 2012;51:1814-9.
20. Touma Z, Gladman DD, Ibanez D, Urowitz MB. SLEDAI-2 K Responder Index 50 captures 50 % improvement in disease activity over 10 years. Lupus. 2012;21:1305-11.
21. Hay EM, Bacon PA, Gordon C, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med. 1993;86:447-58. (Pubitemid 23223653)
22. Stoll T, Stucki G, Malik J, et al. Further validation of the BILAG disease activity index in patients with systemic lupus erythematosus. Ann Rheum Dis. 1996;55:756-60. (Pubitemid 26354438)
23. Isenberg DA, Rahman A, Allen E, et al. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. Rheumatology (Oxford). 2005;44:902-6. (Pubitemid 41511186)
24. Yee CS, Farewell V, Isenberg DA, et al. Revised British Isles Lupus Assessment Group 2004 index: a reliable tool for assessment of systemic lupus erythematosus activity. Arthritis Rheum. 2006;54:3300-5. (Pubitemid 44622101)
25. Yee CS, Farewell V, Isenberg DA, et al. British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum. 2007;56:4113-9. (Pubitemid 350262339)
26. Yee CS, Farewell V, Isenberg DA, et al. The BILAG-2004 index is sensitive to change for assessment of SLE disease activity. Rheumatology (Oxford). 2009;48:691-5.
27. Cresswell L, Yee CS, Farewell V, et al. Numerical scoring for the Classic BILAG index. Rheumatology (Oxford). 2009;48:1548-52.
28. Yee CS, Cresswell L, Farewell V, et al. Numerical scoring for the BILAG-2004 index. Rheumatology (Oxford). 2010;49:1665-9.
29. • Yee CS, Gordon C, Isenberg DA, et al. The BILAG-2004 systems tally - a novel way of representing the BILAG-2004 index scores longitudinally. Rheumatology (Oxford). 2012;51:2099-105. A novel alternative approach to longitudinally represent the BILAG-2004 system scores that is both clinically meaningful and easier to analyze compared to multiple catergorical variables.
30. Bonilla-Martinez ZL, Albrecht J, Troxel AB, et al. The cutaneous lupus erythematosus disease area and severity index: a responsive instrument to measure activity and damage in patients with cutaneous lupus erythematosus. Arch Dermatol. 2008;144:173-80. (Pubitemid 351287000)
31. • Klein R, Moghadam-Kia S, LoMonico J, et al. Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus. Arch Dermatol. 2011;147:203-8. Analysis evaluating the use of CLASI in classifying patients according to disease severity and in identifying responders to therapy.
32. Jolly M, Kazmi N, Mikolaitis RA, et al. Validation of the Cutaneous Lupus Disease Area and Severity Index (CLASI) using physician- and patient-assessed health outcome measures. J Am Acad Dermatol. 2012.
33. The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis Rheum. 2006;54:421-432.
34. Petri M, Kasitanon N, Lee SS, et al. Systemic lupus international collaborating clinics renal activity/response exercise: development of a renal activity score and renal response index. Arthritis Rheum. 2008;58:1784-8. (Pubitemid 351847532)
35. Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20:1103-12.
36. Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012;64:1215-26.
37. •• Wofsy D, Hillson JL, Diamond B. Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions. Arthritis Rheum. 2012;64:3660-5. Insightful post hoc analysis of the abatacept lupus nephritis trial dataset by use of previously proposed response criteria that provides an evidence-based rational for choosing among alternative definitions of response.
38. Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis and rheumatism. 2011;63:3918-30.
39. Wallace DJ, Kalunian K, Petri MA, et al. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis. 2013. doi: 10.1136/annrheumdis-2012-202760. [Epub ahead of print].
40. •• Petri M, Pike MC, Kelley L, et al. Systemic Lupus Erythematosus Responder Index Assessment of Responders in EMBLEM, a Phase IIb Study in Patients with Moderate to Severe Systemic Lupus Erythematosus. Arthritis Rheum. 2011;63:S548. Post hoc analysis of the dataset from the phase II EMBLEM study by use of the SRI in comparison to BICLA.
41. • Sridharan ST, Zhou T, Immermann F, et al. Low Placebo Responses and Clinical Components of the Biomarkers of Lupus Disease (BOLD) Study May Provide Useful Insights for Systemic Lupus Erythematosus Clinical Trial Design. Arthritis Rheum. 2011;63:S552. Comparion of the SRI and BICLA to the simpler BOLD improvement criteria anchored to the clinician's impression of response.
42. • Ruperto N, Hanrahan LM, Alarcon GS, et al. International consensus for a definition of disease flare in lupus. Lupus. 2011;20:453-62. Consensus definition of disease flare in lupus derived by a international working group of physicians after a formal DEPHI exercise.
43. •• Isenberg DA, Allen E, Farewell V, et al. An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA. Ann Rheum Dis. 2011;70:54-9. Comparison of flares defined by the BILAG-2004 flare index and the SELENA flare index in a real world exercise that also incorporated the physician's global assessment and a panel assessment of flares.
44. Kalunian K, Merrill JT, Maciuca R, et al. Efficacy and Safety of Rontalizumab (Anti-Interferon Alpha) in SLE Subjects with Restricted Immunosuppressant Use: Results of A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study. Arthritis Rheum. 2012;64:S1123.
45. Gordon C, Sutcliffe N, Skan J, et al. Definition and treatment of lupus flares measured by the BILAG index. Rheumatology (Oxford). 2003;42:1372-9. (Pubitemid 37407029)